Literature DB >> 16573403

Cardiac arrhythmias: diagnosis and management. The bradycardias.

D Durham1, L I G Worthley.   

Abstract

OBJECTIVE: To review the diagnosis and management of cardiac arrhythmias in a two-part presentation. DATA SOURCES: Articles and published peer-review abstracts on tachycardias and bradycardias. SUMMARY OF REVIEW: Bradycardias are caused by a failure of the sinus node to generate normal impulses or due to a defect in cardiac conduction that in turn causes a delay or failure of impulse propagation. During sleep, the heart rate may decrease to 30 beats per minute (bpm) with episodes of sinoatrial block, junctional rhythms and first and second degree atrioventricular block that occur often enough (particularly in trained athletes) to be considered normal variants. However, treatment is required if symptoms of dizziness, confusion, fatigue Stokes-Adams attacks or heart failure occur. Sinus node dysfunction or 'sick sinus syndrome' is usually caused by intrinsic nodal disease and may present with episodes of tachycardia and bradycardia (tachycardia-bradycardia syndrome). Treatment usually requires a permanent pacemaker. Atrioventricular (AV) conduction disturbances are characterised by a delay or failure of the atrial impulse to be conducted through the AV conducting system. If the escape rhythm is unstable the patient also requires a pacemaker. In the critically ill patient tachycardias are more often encountered than bradycardias. However, the intensivist should be familiar and skilled in the management of complete heart block and asystole, correcting the underlying defect (drug toxicity, hyperkalaemia, etc), while using catecholamines, atropine aminophylline and a temporary pacemaker for initial resuscitation.
CONCLUSIONS: Bradycardias are uncommon in the critically ill patient and often are caused by an underlying disorder (e.g. hyperkalaemia, calcium channel blocker toxicity, beta adrenergic receptor blocker toxicity, etc). However, post cardiac bypass and acute myocardial infarction may cause cardiac conduction defects that may require urgent resuscitation with a temporary pacemaker.

Entities:  

Year:  2002        PMID: 16573403

Source DB:  PubMed          Journal:  Crit Care Resusc        ISSN: 1441-2772            Impact factor:   2.159


  6 in total

1.  The role of Shox2 in SAN development and function.

Authors:  Hongbing Liu; Ramón A Espinoza-Lewis; Chaohui Chen; Xuefeng Hu; Yanding Zhang; Yiping Chen
Journal:  Pediatr Cardiol       Date:  2012-02-04       Impact factor: 1.655

2.  Shox2 is essential for the differentiation of cardiac pacemaker cells by repressing Nkx2-5.

Authors:  Ramón A Espinoza-Lewis; Ling Yu; Fenglei He; Hongbing Liu; Ruhang Tang; Jiangli Shi; Xiaoxiao Sun; James F Martin; Dazhi Wang; Jing Yang; YiPing Chen
Journal:  Dev Biol       Date:  2009-01-03       Impact factor: 3.582

3.  Phosphorylation of Shox2 is required for its function to control sinoatrial node formation.

Authors:  Hongbing Liu; Chao-Hui Chen; Wenduo Ye; Ramón A Espinoza-Lewis; Xuefeng Hu; Yanding Zhang; YiPing Chen
Journal:  J Am Heart Assoc       Date:  2014-05-20       Impact factor: 5.501

4.  PDGFRα-Signaling Is Dispensable for the Development of the Sinoatrial Node After Its Fate Commitment.

Authors:  Xi Zheng; Fengjiao Wang; Xiaoxiao Hu; Hua Li; Zhen Guan; Yanding Zhang; Xuefeng Hu
Journal:  Front Cell Dev Biol       Date:  2021-06-10

5.  Ablation of RIC8A function in mouse neurons leads to a severe neuromuscular phenotype and postnatal death.

Authors:  Katrin Ruisu; Keiu Kask; Riho Meier; Merly Saare; Raivo Raid; Alar Veraksitš; Alar Karis; Tambet Tõnissoo; Margus Pooga
Journal:  PLoS One       Date:  2013-08-16       Impact factor: 3.240

6.  Chinese medicine shensongyangxin is effective for patients with bradycardia: results of a randomized, double-blind, placebo-controlled multicenter trial.

Authors:  Yunfang Liu; Ning Li; Zhenhua Jia; Feng Lu; Jielin Pu
Journal:  Evid Based Complement Alternat Med       Date:  2014-01-16       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.